EUVIMEDEUVIMED entdecken
Crossref

Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer

Kenta Onishi, Yasushi Nakai iD, Akira Tachibana, Nobutaka Nishimura, Fumisato Maesaka iD, Mitsuru Tomizawa, Yosuke Morizawa iD, Shunta Hori iD, Daisuke Gotoh iD, Makito Miyake iD, Kaori Yamaki, Isao Asakawa und 3 weitere

International Journal of Urology · 2025

DOI: 10.1111/iju.70018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Kenta Onishi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Urology, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Quality of Life, Testosterone, Androgen Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Androgen deprivation therapy is generally administered alongside radiation therapy for intermediate‐ or high‐risk prostate cancer. However, this treatment results in low testosterone levels, even on a short‐term basis. Additionally, after cessation, it may take up to a year for normal testosterone levels to return, which deteriorates quality of life. We investigated the time to testosterone recovery and its association with the hormonal quality of life.

Methods

This study included 210 patients at our hospital who received low‐dose‐rate brachytherapy with short‐term (≤ 6 months) neoadjuvant androgen deprivation therapy. Testosterone recovery consisted of three stages: recovery to supracastrate level (serum total testosterone ≥ 0.5 ng/mL), recovery to nonhypogonadism level (serum total testosterone ≥ 1.31 ng/mL), and recovery to normal level (serum total testosterone ≥ 3 ng/mL).

Results

The median duration for androgen deprivation therapy was 4 months. The median times to testosterone recovery after cessation were 3.2, 4, and 12.1 months for supracastrate, nonhypogonadism, and normal levels, respectively. [Correction added on 28 March 2025, after first online publication: In the preceding sentence, the median times have been corrected from ‘3.3, 5.7, and 12.2 months’ to ‘3.2, 4, and 12.1 months’]. We used the Expanded Prostate Cancer Index Composite questionnaire to evaluate quality of life. The hormonal domain score deteriorated significantly after the initiation of low‐dose‐rate brachytherapy until 6 months after treatment and became comparable to the pre‐treatment level after 12 months. We determined that the questionnaire subscales for hormonal function and bother domains returned to baseline at 12 and 6 months, respectively.

Conclusions

Recovery of total testosterone level after androgen deprivation therapy cessation was a long‐term process. The hormonal bother score improved earlier than the hormonal function score on subscales of the hormonal quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsQuality of LifeTestosteroneAndrogen AntagonistsBrachytherapyHumansMaleAgedMiddle AgedNeoadjuvant TherapyJapanTime FactorsAged, 80 and overRetrospective StudiesEast Asian People

Stichwörter der Autor:innen

Japaneseandrogen deprivation therapyprostate cancerquality of lifetestosterone recovery

Substanzen

TestosteroneAndrogen Antagonists

Autor:innen und Institutionen

  • Departments of Urology, Nara Medical University, Kashihara, Nara, Japan.
  • Departments of Radiation Oncology, Nara Medical University, Kashihara, Nara, Japan.
  • Departments of Prostate Brachytherapy, Nara Medical University, Kashihara, Nara, Japan.

ORCID-Profile: Yasushi Nakai, Fumisato Maesaka, Yosuke Morizawa, Shunta Hori, Daisuke Gotoh, Makito Miyake, Kiyohide Fujimoto, Nobumichi Tanaka

Zitieren

APA

Onishi, K., Nakai, Y., Tachibana, A., Nishimura, N., Maesaka, F., Tomizawa, M., Morizawa, Y., Hori, S., Gotoh, D., Miyake, M., Yamaki, K., Asakawa, I., Isohashi, F., Fujimoto, K., & Tanaka, N. (2025). Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70018

Vancouver

Onishi K, Nakai Y, Tachibana A, Nishimura N, Maesaka F, Tomizawa M, et al. Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer. International Journal of Urology. 2025. doi:10.1111/iju.70018

BibTeX
@article{Onishi2025,
  author = {Onishi, Kenta and Nakai, Yasushi and Tachibana, Akira and Nishimura, Nobutaka and Maesaka, Fumisato and Tomizawa, Mitsuru and Morizawa, Yosuke and Hori, Shunta and Gotoh, Daisuke and Miyake, Makito and Yamaki, Kaori and Asakawa, Isao and Isohashi, Fumiaki and Fujimoto, Kiyohide and Tanaka, Nobumichi},
  title = {Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70018}
}
Kostenlos starten →